TY - JOUR
T1 - In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes
AU - Cern, Ahuva
AU - Connolly, Kristie L.
AU - Jerse, Ann E.
AU - Barenholz, Yechezkel
N1 - Publisher Copyright:
Copyright © 2018 American Society for Microbiology. All Rights Reserved.
PY - 2018/4
Y1 - 2018/4
N2 - Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.
AB - Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.
KW - Antibiotic resistance
KW - Antimicrobial activity
KW - Antimicrobial resistance
KW - Cross-resistance
KW - Liposomes
KW - Nano-mupirocin
UR - http://www.scopus.com/inward/record.url?scp=85043395834&partnerID=8YFLogxK
U2 - 10.1128/AAC.02377-17
DO - 10.1128/AAC.02377-17
M3 - Article
C2 - 29339382
AN - SCOPUS:85043395834
SN - 0066-4804
VL - 62
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 4
M1 - e02377-17
ER -